Brief: HanAll Biopharma, Daewoong Pharma And NurrOn Pharma Complete First Human Study for Parkinson's Therapy
25/11/2024 14:45
Nov 25 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA, DAEWOONG PHARMACEUTICAL AND NURRON
PHARMACEUTICALS ANNOUNCE SUCCESSFUL COMPLETION OF A
FIRST-IN-HUMAN STUDY FOR POTENTIAL DISEASE-MODIFYING THERAPY FOR
PARKINSON'S DISEASE
* HANALL BIOPHARMA CO LTD: HL192 (ATH-399A) WAS WELL
TOLERATED
WITH NO MAJOR SAFETY ISSUES IN ANY OF THE 76 PARTICIPANTS
Source text: ID:nPn8NCFHpa
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies